FitLife Brands, Inc. (FTLF) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. FitLife Brands, Inc. is a provider of nutritional supplements and wellness products operating under four primary brand groups: NDS Products (distributed via GNC), iSatori Products (retail and online), MRC Products (primarily online, including Dr. Tobias), and MusclePharm (wholesale and online). The company is headquartered in Omaha, Nebraska, and trades on the Nasdaq Capital Market.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $16.93 million | $14.76 million | $33.48 million | $25.50 million |
| Gross Profit | $7.58 million | $5.97 million | $14.87 million | $10.37 million |
| Gross Margin | 44.8% | 40.4% | 44.4% | 40.7% |
| Operating Income | $3.68 million | $2.58 million | $7.06 million | $3.26 million |
| Net Income | $2.63 million | $1.96 million | $4.79 million | $2.12 million |
| Diluted EPS | $0.53 | $0.40 | $0.97 | $0.43 |
| Cash & Equivalents | $3.68 million | N/A | N/A | N/A |
| Operating Cash Flow (YTD) | N/A | N/A | $6.61 million | $1.79 million |
| Total Debt (Term Loans) | $15.38 million | N/A | N/A | N/A |
Note: All figures in millions unless otherwise noted. Debt figures represent outstanding term loans as of June 30, 2024.
Material Changes vs. Prior Period
- Revenue Growth: Q2 2024 revenue increased 15% year-over-year, driven primarily by the full-quarter contribution of the MusclePharm acquisition (acquired Oct 2023) and MRC (acquired Feb 2023). Legacy FitLife revenue declined 5% due to a 10% drop in wholesale sales, partially offset by a 7% increase in online sales.
- Margin Expansion: Gross margin improved to 44.8% from 40.4% in Q2 2023. This was aided by higher margins from MRC and the absence of inventory step-up amortization impacts that affected the prior year.
- Expense Management: Advertising and marketing expenses decreased 9% in Q2 2024 due to rationalization of less effective campaigns. However, SG&A increased 42% due to Amazon product testing costs and headcount additions related to the MusclePharm integration.
- Debt Reduction: The company made a voluntary prepayment of $2.5 million on Term Loan A in Q1 2024, reducing total term loan principal from $20.13 million (Dec 2023) to $15.38 million (June 2024).
Outlook, Risks, and Management Commentary
- Strategic Focus: Management continues to prioritize higher-margin online sales channels. Online revenue now represents approximately 66% of total net revenue.
- Acquisition Performance:
- MusclePharm: Generated $2.67 million in Q2 2024 revenue. Management is investing in advertising to drive growth, which temporarily pressured contribution margins.
- MRC: Revenue declined 2% YoY, but gross profit increased 21% and contribution increased 61% following the exit of unprofitable international markets for skin care brands.
- Liquidity: The company maintains positive working capital of $4.71 million. Management believes cash flow from operations and the $3.5 million Line of Credit (currently $0 utilized) are sufficient for the next 12 months.
- Risks:
- Customer Concentration: GNC accounted for 23% of Q2 2024 revenue. Wholesale revenue remains challenged by declining brick-and-mortar customer counts.
- Debt Covenants: The company must maintain a Fixed Charge Coverage Ratio of at least 1.25 and a Funded Debt to EBITDA Ratio of no more than 2.50. The company was in compliance as of June 30, 2024.
- Goodwill Impairment: Significant goodwill ($13.1 million) and intangible assets ($26.3 million) are on the balance sheet. Fair value is sensitive to stock price fluctuations.
Investor Verification Checklist
- Wholesale Dependency: Verify the trend of wholesale revenue decline and the company's ability to offset this with online growth, specifically regarding the GNC partnership.
- Debt Service Capacity: Confirm continued compliance with debt covenants (Fixed Charge Coverage and Debt/EBITDA) given the $15.4 million term loan balance.
- Acquisition Integration: Monitor the contribution margin trends of the MusclePharm brand as advertising investments ramp up.
- Inventory Valuation: Review the allowance for inventory obsolescence, which decreased from $162k to $69k, and assess if this reflects improved turnover or potential under-reserving.
- Goodwill Sensitivity: Assess the impact of stock price volatility on the potential for future goodwill impairment charges.